(Q48565199)

12 February 2018

title

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. (English)

1 reference

12 February 2018

0 references

0 references

7

F Fazekas

1 reference

12 February 2018

6

N De Stefano

1 reference

12 February 2018

M Filippi

1

1 reference

12 February 2018

M A Rocca

2

1 reference

12 February 2018

D L Arnold

3

1 reference

12 February 2018

R Bakshi

4

1 reference

12 February 2018

F Barkhof

5

1 reference

12 February 2018

E Frohman

8

1 reference

12 February 2018

J S Wolinsky

9

1 reference

12 February 2018

publication date

1 April 2006

1 reference

12 February 2018

European Journal of Neurology

published in

1 reference

12 February 2018

volume

13

1 reference

12 February 2018

issue

4

1 reference

12 February 2018

page(s)

313-325

1 reference

12 February 2018

The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Management of acute optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance imaging of the optic nerve in optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Optic neuritis: MR imaging with combined fat- and water-suppression techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Serial magnetization transfer imaging in acute optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Assessment of MRI criteria for a diagnosis of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

MRI techniques to monitor MS evolution: the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

From enhancing lesions to brain atrophy in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Current approved options for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Central nervous system atrophy and clinical status in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of whole-brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Total brain N-acetylaspartate: a new measure of disease load in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

European Study on Intravenous Immunoglobulin in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

10.1111/J.1468-1331.2006.01543.X

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

16643308

1 reference

12 February 2018